Modality
ERT
MOA
KRASG12Ci
Target
TIGIT
Pathway
NF-κB
EpilepsyObesity
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
Mar 2019
→ Jun 2026
Phase 1Current
NCT06422837
1,270 pts·Obesity
2019-03→2025-09·Recruiting
NCT07029718
1,895 pts·Obesity
2020-05→2026-06·Active
3,165 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2025-08-028mo agoPDUFA· Obesity
2025-09-057mo agoInterim· Obesity
2026-06-213mo awayInterim· Obesity
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Recruit…
P1
Active
Catalysts
PDUFA
2025-08-02 · 8mo ago
Obesity
Interim
2025-09-05 · 7mo ago
Obesity
Interim
2026-06-21 · 3mo away
Obesity
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06422837 | Phase 1 | Obesity | Recruiting | 1270 | PFS |
| NCT07029718 | Phase 1 | Obesity | Active | 1895 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT |